| Literature DB >> 31417658 |
Taohong Pang1,2, Yan Zhao3, Ting Fan4, Qingqing Hu1, Dekusaah Raymond4, Shouli Cao1, Weijie Zhang5, Yi Wang1, Bin Zhang1, Ying Lv1, Xiaoqi Zhang1, Tingsheng Ling1, Yuzheng Zhuge1, Lei Wang1, Xiaoping Zou1, Qin Huang1,6, Guifang Xu1,4.
Abstract
BACKGROUND AND AIMS: Endoscopic resection is increasingly performed for gastric gastrointestinal stromal tumors (GIST). However, the safety and outcomes remain elusive. We aimed in this retrospective study to compare operative complications and prognosis between endoscopically and surgically resected small (≤ 5 cm) GIST tumor groups.Entities:
Keywords: Adjuvant therapy with imatinib; Endoscopic resection; Gastric gastrointestinal stromal tumors; Operative complications; Postoperative course; Surgical resection
Year: 2019 PMID: 31417658 PMCID: PMC6692613 DOI: 10.7150/jca.29443
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Flowchart for patient selection and grouping
Figure 2Procedures of STER. (A) Endoscopic view of tumors located in the gastric cardia with a broad-based protruding growth pattern and a smooth surface in size of 1.3 x 1.0 cm. (B) Establishment of a submucosal tunnel. (C、D) A SET was exposed and completely resected. (E、F) After removal of the tumor, no major adverse events occurred and the wound was closed with clips.
Proposed modification of NIH consensus classification criteria for defining risk of aggressive clinical course of primary GISTs 30
| Risk category | Tumor size(cm) | Mitotic index (per 50 HPFS) | Primary tumor site |
|---|---|---|---|
| Very low risk | <2.0 | ≤5 | Any |
| Low risk | 2.1-5.0 | ≤5 | Any |
| Intermediate risk | 2.1-5.0 | >5 | Gastric |
| High risk | <5.0 | 6-10 | Any |
| 5.1-10.0 | ≤5 | Gastric | |
| Any | Any | Tumor rupture | |
| >10 | Any | Any | |
| Any | >10 | Any | |
| >5.0 | >5 | Any | |
| 2.1-5.0 | >5 | Non-gastric | |
| 5.1-10.0 | ≤5 | Non-gastric |
Comparison of Demographics, Tumor Size and Location between Endoscopic and Surgical Groups.
| Total(n=409) | Endoscopy group(n=268) | Surgery group(n=141) | P value | |
|---|---|---|---|---|
| Age (year, mean±SD) | 59.0±9.8 | 58.9±9.5 | 59.1±10.8 | NS |
| Gender (number, %) | < 0.05 | |||
| Male | 166(40.6) | 97(36.2) | 69(48.9) | |
| Female | 243(59.4) | 171(63.8) | 72(51.1) | |
| Male-Female Ratio | 0.68 | 0.57 | 0.96 | |
| Tumor size (cm) (mean±SD) | 2.23±1.2 | 1.69±0.9 | 3.20±1.2 | <0.0001 |
| Tumor location (number, %) | <0.0001 | |||
| Cardia | 44(10.8) | 35(13.1) | 9(6.4) | |
| Fundus | 225(55.0) | 158(58.9) | 67(47.5) | |
| Corpus | 113(27.6) | 64(23.9) | 49(34.8) | |
| Antrum-pylorus | 28(6.6) | 11(4.1) | 16(11.3) |
NOTE: SD: standard deviation; NS: not significant.
Clinicopathological Outcomes of GIST Resection
| Total | Endoscopy group | Surgery group | P value | |
|---|---|---|---|---|
| Total number | 409 | 268 | 141 | |
| Complication | 24(5.9) | 9(3.4) | 15(10.6) | <0.05 |
| Intraoperative major bleeding(≥ 200ml) | 8(2.0) | 0(0) | 8(5.7) | |
| Postoperative hemorrhage | 3(0.7) | 3(1.1) | 0(0) | |
| Postoperative perforation | 1(0.2) | 1(0.4) | 0(0) | |
| Infection | 9(2.2) | 2(0.7) | 7(5.0) | |
| Pneumoperitoneum | 3(0.7) | 3(1.1) | 0(0) | |
| Resection margin | <0.01 | |||
| R0 | 390(95.4) | 250(93.3) | 140(99.3) | |
| R1 | 19(4.6) | 18(6.7) | 1(0.7) | |
| R2 | 0(0.0) | 0(0.0) | 0(0.0) |
Figure 4The distribution of the mitotic index (MI) among all 409 patients according to tumor sizes.
Comparison of Adjuvant Imatinib-treated Patients with Intermediate or High Risk of Aggressiveness between Endoscopy and Surgery Groups.
| Treatment Duration | Total | Endoscopy Group | Surgery Group | P Value |
|---|---|---|---|---|
| 0.591 | ||||
| Total Number | 50 | 23 | 27 | |
| None | 31(62.0) | 13(56.5) | 17(63.0) | |
| 1 to 3 Months | 8(16.0) | 5(21.7) | 3(11.1) | |
| 1 Year | 8(16.0) | 3(13.0) | 5(18.5) | |
| 3 Years | 4(8) | 2(8.8) | 2(7.4) |
Comparisons of Post-resection Hospital Course
| Endoscopy group | Surgery group | P value | |
|---|---|---|---|
| Total Number | 268 | 141 | |
| Time to first fluid diet(days), | 1.9±1.1 | 4.6±2.6 | <0.001 |
| Postoperative length of hospital stay (days) | 4.7±1.5 | 8.1±5.0 | <0.001 |
| Hospitalization expenses (RMB) | 20115.4±5113.5 | 4.3378.4±16795.7 | <0.001 |
Note: RMB: Renmingbi (The Chinese currency)
Comparisons of results between Endoscopic and Surgical Groups after the propensity score matching analysis.
| Resection Outcome | Endoscopy group | Surgery group | ||
|---|---|---|---|---|
| (%) | (%) | |||
| Total Number | 84 | 84 | ||
| Age (year, mean±SD) | 59.5±10.5 | 59.1±10.3 | 0.818 | |
| Gender | 0.276 | |||
| Male | 33(39.3) | 40(47.6) | ||
| Female | 51(60.7) | 44(52.4) | ||
| Tumor size (cm)(mean±SD) | 2.48±1.03 | 2.50±0.96 | 0.854 | |
| Complication | 3(3.6) | 11(13.1) | 0.026 | |
| intraoperative major bleeding(≥200ml) | 0(0) | 5(6.0) | ||
| Postoperative perforation | 1(1.2) | 0(0) | ||
| Infection | 1(1.2) | 6(7.1) | ||
| Pneumoperitoneum | 1(1.2) | 0(0) | ||
| Resection margin | 0.014 | |||
| R0 | 76(90.5) | 83(98.8) | ||
| R1 | 8(9.5) | 1(1.2) | ||
| R2 | 0(0.0) | 0(0.0) | ||
| Time to first liquid diet (days), | 2.1±1.3 | 4.6±3.0 | <0.001 | |
| Postoperative length of hospital stay (days) | 4.9±1.9 | 8.0±5.4 | <0.001 | |
| Hospitalization expenses (RMB) | 21884.3±5960.2 | 40267.2±13954.2 | <0.001 |
Figure 5Kaplan-Meier analysis of overall survival of patients treated with either endoscopy therapy or surgery therapy.